Curated News
By: NewsRamp Editorial Staff
December 18, 2025
Soligenix Reports Promising Phase 2a Results for Behçet's Disease Treatment
TLDR
- Soligenix's SGX945 shows comparable efficacy to apremilast with only four weeks of dosing, offering a potential competitive advantage in treating Behçet's Disease ulcers.
- SGX945 demonstrated beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up after treatment ended, with no treatment-related adverse events observed.
- This treatment could significantly improve quality of life for Behçet's Disease patients by reducing oral ulcers and pain while addressing an unmet medical need.
- Soligenix's novel drug SGX945 achieved results comparable to an established Phase 3 treatment with just four weeks of dosing instead of continuous administration.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough for patients with Behçet's Disease, a rare and chronic inflammatory disorder that causes painful oral ulcers and other symptoms, often with limited treatment options. The study's results suggest SGX945 could offer comparable efficacy to existing therapies like apremilast but with a shorter dosing regimen, potentially reducing long-term side effects and improving patient convenience. If successful in further trials, this could lead to a new, more accessible treatment option, addressing a significant unmet medical need and improving quality of life for those affected. Additionally, Soligenix's broader pipeline, including other rare disease and vaccine programs, underscores the company's role in advancing innovative biopharmaceutical solutions, which could have wider implications for healthcare and public health.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, has announced promising results from its Phase 2a proof-of-concept study for SGX945 (dusquetide) in treating aphthous ulcers associated with Behçet's Disease. Published in the journal Rheumatology (Oxford), the study reported beneficial effects in seven of eight patients, with sustained improvement through a four-week follow-up period after treatment ended. The company highlighted that outcomes for SGX945—including reductions in oral ulcers and pain, along with favorable area under the curve measurements—were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration. Soligenix noted SGX945 was well tolerated with no treatment-related adverse events observed, and it plans to pursue reformulation for home-based subcutaneous administration while expanding dusquetide's development across additional innate immune-related inflammatory conditions. The company is also engaging regulators on a follow-on clinical study for this area of unmet medical need.
Beyond this specific study, Soligenix's Specialized BioTherapeutics business segment is advancing multiple programs, including HyBryte(TM) (SGX301) for cutaneous T-cell lymphoma, synthetic hypericin (SGX302) for psoriasis, and dusquetide (SGX942) for inflammatory diseases like oral mucositis in head and neck cancer. Its Public Health Solutions segment focuses on vaccine candidates such as RiVax(R) for ricin toxin, filovirus vaccines, and CiVax(TM) for COVID-19, supported by government funding from agencies like NIAID, DTRA, and BARDA. This news was distributed via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides extensive wire solutions and syndication to enhance corporate communications. For more details, readers can view the full press release at the provided link.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Reports Promising Phase 2a Results for Behçet's Disease Treatment
